Scientific Presentations, Abstracts, and Posters - Rozanolixizumab Scientific Presentations, Abstracts, and Posters - Rozanolixizumab
CONTENT PROVIDED FOR SHAREHOLDERS, INVESTORS, AND OTHER CAPITAL MARKET PARTICIPANTS ONLY The following documents are specifically for shareholders, investors, and other capital market participants. This webpage is not intended for other members of the general public. If you are not a shareholder, investor, or other capital market participant, please return to UCB's homepage. Rozanolixizumab Presentations, Abstracts, Posters AANEM 2022 Efficacy of rozanolixizumab in MUSK+ gMG: outcomes from the Phase 3 study Safety and tolerability of rozanolixizumab in the randomized Phase 3 study Rozanolixizumab in gMG: responder analyses from the randomized Phase 3 study MGFA Meeting 2022 Rozanolixizumab in gMG Phase 3 Results Poster Rozanolixizumab in gMG Patient Reported Outcomes and Quality of Life Results Poster Real-World Data from Patients with Myasthenia Gravis Using Smartphones Poster
